Gatifloxacin

These indications are based on manufacturer information for both originator and generic products. For product specific registered indications, please refer to product specific manufacturer information

Registered South African indications:

• Bacterial conjunctivitis caused by susceptible strains of: Aerobic Gram-positive bacteria (Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis, Streptococcus pneumoniae) and  Aerobic Gram-negative bacteria (Haemophilus influenzae)

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Hypersensitivity to other quinolones

Cautions

• Pregnancy
• Breastfeeding
• Prolonged use
• Concomitant use of contact lenses

Forms avail. in SA and covered in this monograph: opd

Infections caused by Gram positive aerobic cocci (excluding methicillin-resistant S. aureus); Gram negative anaerobic bacilli (excluding Enterobacteriaceae and P. aeruginosa)

Specific doses based on individual indications

Please note that the dosages below should be used in combination with regional guidelines, taking into account local antibiotic sensitivities

Bacterial conjunctivitis

• Ophthalmic (opd): Day 1-2: 1 drop into affected eye(s), 2hrly, while awake; Max: 8 drops/day; Day 3-7: 1 drop into affected eye(s), 6hrly, while awake

Paed. forms avail. in SA and covered in this monograph: opd

Infections caused by Gram positive aerobic cocci (excluding methicillin-resistant S. aureus); Gram negative anaerobic bacilli (excluding Enterobacteriaceae and P. aeruginosa)

Specific doses based on individual indications

Please note that the dosages below should be used in combination with regional guidelines, taking into account local antibiotic sensitivities

Bacterial conjunctivitis

Younger than 1 year

• Not established for use

Older than 1 year

• See adult dosage

Pregnancy

• FDA Pregnancy Category C

Breastfeeding

• Caution; not recommended

Renal Impairment

• No dose adjustment recommended

Hepatic Impairment

• No dose adjustment recommended

Elderly

• No dose adjustment recommended

Central Nervous System Disorders

• Headache 

Gastrointestinal Disorders

• Taste disturbance 

Skin and Subcutaneous Tissue Disorders

• Erythema

Sensory Disorders

• Conjunctivitis
• Keratitis
• Papillary conjunctivitis
• Increased lacrimation
• Conjunctival disorder 
• Eyelid oedema
• Reduced visual acuity
• Red eye
• Eye irritation
• Eye pain
• Eye discharge
• Dry eye
• Conjunctival haemorrhage
• Chemosis

No information available

None routine

The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of chromosomal DNA during bacterial cell division.

Spectrum of activity: Gram positive aerobic cocci (excluding methicillin-resistant S. aureus); Gram negative anaerobic bacilli (excluding Enterobacteriaceae and P. aeruginosa)

Eye drops (per ml) 3mg

• Zymar (Allergan) originator